Results for “ ”

Entry Author Date Location
FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer 10/25/16 National
Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo 10/21/16 National
Alkermes Eyes FDA Nod After Retooled Study Yields Desired Results 10/20/16 Boston
Fred Hutch Team Wants To Move Clean-Room Gene Therapy To Tabletop 10/20/16 Seattle
BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders 10/20/16 San Francisco
Here’s the Agenda for What’s Hot in Boston Healthtech on Nov. 17 10/19/16 Boston
Arterys, GE Healthcare to Roll Out Next-Gen MRI Scans of Heart 10/19/16 San Francisco
All In One Place: A New Immuno-Oncology Trial Resource 10/19/16 National
At NY Life Sci 2021, Yancopoulos, Dunn & More to Ponder NYC’s Bio Future 10/19/16 New York
CRISPR Therapeutics Raises $56M In IPO, Half Its Rivals’ Haul 10/18/16 Boston
After “Hubris” and Its HCV Collapse, Can Vertex Avoid Same Mistakes? 10/18/16 Boston
Veritas Genetics Lands $30M for $1,000 Genome Sequencing 10/17/16 Boston
Last Chance to Save on Boston’s Life Science Disruptors on 10/20 10/17/16 Boston
Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs 10/17/16 New York
Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More 10/14/16 National
Iora Health Dials Up $75M to Expand Primary Care Clinics 10/13/16 Boston
With Upgraded Tech, Bluebird Updates Regulatory Path For Gene Therapy 10/13/16 Boston
Aquaculture Industry Casts Wider Net in Food and Consumer Markets 10/13/16 Raleigh Durham
Ocular Therapeutix Inks Licensing Deal With Regeneron For Wet AMD 10/13/16 Boston
Bay Area Researchers Take A CRISPR Cut At Sickle Cell Disease 10/12/16 San Francisco
Procrastinator’s Special Ends Thursday for Boston’s Life Science Disruptors 10/12/16 Boston
Checkpoints In Lung Cancer, and Other Oncology News From Europe 10/11/16 National
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More 10/07/16 National
Intellia Execs Talk CRISPR’s Path Forward at Xconomy’s Oct. 20 Event 10/06/16 Boston
Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge 10/05/16 Boston
With New Program, DARPA To Encourage Safety “Brakes” For Gene Editing 10/05/16 National
Post FDA Approval, Sarepta Wheels and Deals for Combo Duchenne Drugs 10/04/16 Boston
Still Stuck Below IPO Price, Merrimack Restructures, CEO Resigns 10/03/16 Boston
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue 10/03/16 Boston
Page 1 of 114 next page »